Cis-platinum-adriamycin-cyclophosphamide in the treatment of advanced-recurrent cervical cancer.
Twenty-two patients with advanced or recurrent cancer of the cervix treated with cis-platinum, adriamycin and cyclophosphamide were evaluated. Nine of 22 (41% achieved objective response (2 CR + 7PR), 9/22 (41%) stable disease, 4/22 (18%) progressive disease. The mean duration of response was 24.6 weeks, with a range of 18-28 weeks. Patients with poorly differentiated histologic grade and without previous treatment had better response rates. Responders had longer survival (mean 63.5 + weeks) than nonresponders (mean 30.5 weeks). Commonly encountered toxicities were alopecia, nausea and vomiting, and leucopenia, which were all tolerable.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin